- EnteroMedics Inc ETRM shares surged 73.3 percent to $6.88. EnteroMedics shares have jumped 120.56 percent over the past 52 weeks, while the S&P 500 index has gained 14.01 percent in the same period.
- SunLink Health Systems, Inc. SSY shares jumped 30.4 percent to $1.46. SunLink Health announced plans to buyback 3 million shares at $1.50 per share.
- Zafgen Inc ZFGN shares jumped 21.2 percent to $4.06g after gaining 0.60 percent on Thursday.
- Quotient Ltd QTNT shares gained 16.7 percent to $6.29 after the company reported positive MosaiQ results from its performance evaluation study.
- Stemline Therapeutics Inc STML shares climbed 14.2 percent to $12.96 after the company reported a FDA deal on expedited pathway to full approval of SL-401 in first-line BPDCN.
- Pacira Pharmaceuticals Inc PCRX shares surged 14.2 percent to $39.00. Pacira Pharmaceuticals reported preliminary 2016 revenue of $276.4 million.
- Cempra Inc CEMP shares gained 12.3 percent to $3.65.
- Abeona Therapeutics Inc ABEO climbed 6.7 percent to $5.97. Jefferies initiated coverage on Abeona Therapeutics with a Buy rating.
- Healthways, Inc. HWAY shares rose 6.5 percent to $24.75. Jefferies upgraded Healthways from Hold to Buy.
- Helen of Troy Limited HELE shares climbed 6.4 percent to $95.00. Helen of Troy reported better-than-expected earnings for its third quarter, but sales missed expectations. The company raised its earnings forecast for the year, but lowered its sales outlook.
- Ionis Pharmaceuticals Inc IONS shares gained 5.5 percent to $49.66 after the company reported a licensing deal with Novartis AG (ADR) NVS.
- CTI BioPharma Corp CTIC shares rose 4.5 percent to $4.66 after surging 12.34 percent on Thursday.
- Neurocrine Biosciences, Inc. NBIX shares rose 4.4 percent to $43.19. Neurocrine issued an update on FDA Advisory Committee for INGREZZA for the treatment of tardive dyskinesia.
- Amgen, Inc. AMGN rose 3.3 percent to $157.96 after the company disclosed that it has won a court ruling for a ban on Sanofi's sales of praluent cholestrol drug.
- Gap Inc GPS rose 2.4 percent to $23.80. Gap reported a 2 percent year-over-year gain in its comparable sales for the November and December 2016 holiday season. Gap comparable sales for December rose 4 percent, compared to a 5 percent decline last year.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
